Evan Scott
Northwestern University
Reroutes rapamycin to antigen-presenting cells to induce lasting immune tolerance in type 1 diabetes.
Sponsored researchIn-development
Get the Discover digest
Receive a weekly email digest of the latest chronic disease management solutions added by the network.Discover innovations in chronic disease management
Get the Discover digest
Receive a weekly email digest of the latest chronic disease management solutions added by the network.Browse 333 solutions in chronic disease management on the Halo network
Updated Nov 2, 2026
Chronic disease management covers the therapies and delivery systems built for conditions people live with for years. On Halo, the solutions cover immune tolerance in diabetes, non-opioid chronic pain, chronic inflammation and autoimmunity, and organ-specific chronic disease. Sign up to search the full network and post your specific need.
Immune tolerance in diabetes
Evan Scott
JJ
Adoptracell, INC. · Supplier
CAR-Treg cells targeting GAD65, aimed at the autoimmune cause of type 1 diabetes and not the glucose.
Sponsored researchEarly-stage
RS
Sunnybrook Health Sciences Centre · University
Inhibits ROMO1 in the liver as a route to weight loss and type 2 diabetes control.
In-development
MF
SFA Therapeutics · Supplier
Bacterial metabolites acting as natural GLP-1 agonists, taken orally.
Early-stage
Non-opioid chronic pain
MH
University of Arizona
Mas receptor agonists designed to damp the inflammatory pathways behind chronic neuropathic pain.
Co-developmentIn-development
Pieter Gaillard
Eyesiu Medicines BV · Supplier
A sublingual PEA spray for fast relief in chronic and neuropathic pain.
In-development
FE
Council for Scientific and Industrial Research · University
Microneedle patches delivering cannabinoids through the skin for controlled pain relief.
In-development
Chronic inflammation and autoimmunity
Pablo Scodeller
Consejo Superior de Investigaciones Científicas · University
An oral peptide-drug conjugate that targets CD206+ macrophages in Crohn's disease.
Co-developmentEarly-stage
MF
Short-chain fatty acid formulations that act epigenetically on chronic inflammatory conditions.
Sponsored researchEarly-stage
Elizabeth Sharlow
KeViRx, Inc. · Supplier
A host-directed small molecule that stabilizes the endothelial barrier against microvascular leakage.
LicensingIn-development
Organ-specific chronic disease
DO
University of Kentucky
Predicts the onset and progression of chronic kidney disease from routine health records and claims, with no extra tests.
LicensingIn-development
M3
M3Nephron · Startup
Dialyzer membranes that combine diffusion and adsorption to clear more uremic toxins using less dialysate.
In-development
You're viewing a preview of chronic disease management solutions on Halo.
Sign up free to search the full network and post your specific need.
Already have an account?
Who is working on chronic disease management
Organizations in chronic disease management
Universities, startups, and suppliers with solutions in chronic disease management.
Chronic disease management organizations
Innovators in chronic disease management
Researchers and inventors advancing chronic disease management.
Chronic disease management expertsAbout chronic disease management
Chronic disease management on Halo is mostly therapeutics: immune tolerance for type 1 diabetes, non-opioid routes to chronic pain, and long-acting depots that cut how often a patient has to dose. On Halo it spans four groups, including immune tolerance in diabetes, non-opioid chronic pain, and chronic inflammation and autoimmunity.
Stage of development. Work on chronic disease management on Halo comes mostly from university programs. 35% of the solutions are in market. Co-development and licensing are the usual partnering routes, and about 54% of the solutions that state terms offer pilot engagements.
Three trends in chronic disease management on Halo
Teaching the immune system in place of suppressing it. Two type 1 diabetes programs go after the autoimmunity and not the glucose. One reroutes rapamycin to antigen-presenting cells for long-lived tolerance; another builds CAR-Treg cells against GAD65. Both aim to stop the attack and not replace what it destroys.
Chronic pain with no opioids. The pain cluster is entirely non-opioid: Mas receptor agonists against the inflammatory pathway, a sublingual PEA spray, cannabinoid microneedle patches, and a combination built for diabetic peripheral neuropathy. Route of delivery is doing as much work as the molecule.
Dosing less often. Long-acting formats recur. A peptide hydrogel depot releases anti-TNF antibodies slowly through dynamic covalent bonding, and microneedle patches hold cannabinoids at a controlled rate. For a condition measured in decades, the interval between doses is part of the therapy.
334organizations
333solutions listed
63%from university labs
35%in market
Frequently asked questions
What is chronic disease management?
Chronic disease management covers the therapies and delivery systems built for conditions a patient lives with for years, not episodes that resolve. It spans immune tolerance approaches in autoimmune disease, non-opioid routes to persistent pain, long-acting depots that cut dosing frequency, and the formulations that make daily treatment tolerable. Pharmaceutical developers and specialty care providers are the buyers.
What are examples of chronic disease management?
Four examples of chronic disease management solutions on Halo include:
- Reroutes rapamycin to antigen-presenting cells to induce lasting immune tolerance in type 1 diabetes. (Northwestern University)
- Mas receptor agonists designed to damp the inflammatory pathways behind chronic neuropathic pain. (University of Arizona)
- An oral peptide-drug conjugate that targets CD206+ macrophages in Crohn's disease. (Consejo Superior de Investigaciones Científicas)
- Improves mitochondrial health to slow autosomal dominant polycystic kidney disease. (University of Southern California)
What are the latest chronic disease management innovations?
The most recently updated chronic disease management solutions on Halo include:
Which companies and suppliers are developing chronic disease management?
There are 334 organizations with chronic disease management solutions on Halo, 47 of them universities and research institutions. Among them are Northwestern University, Adoptracell, INC., and Sunnybrook Health Sciences Centre. Most offer co-development or licensing. Sign up to see every organization working in the area and to send them your specific need.
How do I find chronic disease management research partners?
Browsing chronic disease management solutions on Halo is free. Sign up to search the full network and save the ones you want. Post your specific need to get exact matches. Organizations reply directly on the platform.
What are R&D teams looking for in chronic disease management?
Over the past 12 months, R&D teams on Halo have posted these chronic disease management needs:
Related medicine research areas
Pharmaceuticals and drug deliveryRegenerative medicineMedical diagnosticsVaccine developmentPersonalized medicineMedical imagingSurgical technologiesOncology & cancer therapeuticsInfectious disease & antimicrobialsNeurology & neurological diseaseImmunology & immune-mediated diseaseBrowse all medicine solutions
Confirm digest type